The war on smoking is fascinatingly perverted. Big Money indeed. Bloomberg Territory in fact. Investment and profit, wealth and riches unimaginable - and power.
Big Drug's Nicotine War
The PDF link I have posted here is an interesting read. This history of NRT only goes to 2001 - what a pity! However, it is also a history for vapers. Nicotine has been a most profitable industry for the Cigarette Industry AND Pharmaceuticals. There's GOLD IN NICOTINE. Big Pharma have been inside Tobacco Control from the beginning. Their involvement in the anti-smoking drive has been so deep they must be absolutely horrified that electronic cigarettes, not invented by themselves, and so utterly disruptive to the whole smoking/pharma symbiosis have taken off. Many vapers prefer vaping to smoking, and millions have dropped tobacco smoking. It makes Tobacco Control, and all its minion lobby groups like Ash look old fashioned and redundant. The whole Industry must be in crises. No wonder they don't want VAPERS to VAPE. We might discover more benefits to vaping than meets the eye. It's our alluring 2nd and 3rd generational delivery systems that is making them retch because it's OUR goldmine not theirs!
III - Gold In Nicotine
Publication date July 13, 2001
“It helps digestion, the gout, the toothache, prevents infection by scents; it heats the cold, and cools them that sweat,feedeth the hungry, spent spirits restoreth, purgeth the stomach,killeth nits and lice; the juice of the green leaf healeth green wounds, although poisoned; the syrup for many diseases; the smoke for the phthisic, cough of the lungs, distillations of rheum, and all diseases of a cold and moist cause; good for all bodies cold and moist taken upon an empty stomach; taken upon a full stomach it precipitates digestion.” John Josselyn on the medicinal uses of tobacco, 1675 (quoted in .A.Weslager, Magic Medicines of the Indians, Signet, NY: 1974)
“Nicotine is an amazing chemical.”Jack Henningfield, 1998 (quoted in “Smoking Aside, Nicotine Remains an Amazing Chemical,” Scott Shane,The Seattle Times, 1/11/98, p. A10).Henningfield, a pharmacologist at Johns Hopkins and former National Institute of Drug Abuse scientist, is also a consultant to SmithKlineBeecham.
Tobacco was used medicinally by the indigenous populations in the Americas long before the arrival of European settlers. After the Europeans began to colonize the New World, they too used it to treat numerous physical diseases and complaints, a practice which continued in American folk remedies until well into the 20th century.
However, as the anti-tobacco movement gained strength and momentum in the 1980s, both tobacco and the nicotine it contained were excoriated by public health officials. And in 1988 the U.S. Surgeon General’s report for the first time asserted that nicotine was an addictive drug, chaining smokers to their cigarettes. This claim has become a favored weapon not only of the anti-tobacco establishment but also of trial attorneys attempting to win huge sums of money in lawsuits against the tobacco industry.
Pharmacolgists and other scientists, who had been investigating the physiological effects of nicotine since at least the 1950s, began to find that nicotine could have significant therapeutic applications, both as a stop-smoking aid and as a medicine for treating various diseases. Their interest in nicotine increased as new discoveries about the substance emerged.
A time-specific online search of the National Library of Medicine’s PubMed database demonstrates quite well the pattern of increasing scientific interest in nicotine. Between 1963 (the earliest publication year PubMed indexes) and 1970, 1092 articles on nicotine are listed; between 1971 and 1980, 2346 articles are listed; between 1981 and 1990, 3771 articles are listed; and between 1991 and 2000, 6919 articles are listed. In other words, in thirty-seven years, published research involving nicotine multiplied by more than a factor of six.
The pharmaceutical industry had seen for some time the potential profits in developing nicotine-based smoking-cessation drugs. In 1962, Pharmacia’s scientists began working on such nicotine delivery devices, and by 1971 they had perfected nicotine-laden gum, which was later marketed by SmithKlineBeecham as Nicorette. As the anti-tobacco movement grew, other pharmaceutical companies became interested in the potentially huge market for smoking-cessation products. When researcher Jed Rose developed the transdermal nicotine patch in the early 1980s, the pharmaceutical industry was quick to begin steps to bring it to market. It wasn’t just the smoking-cessation applications of alternate nicotine delivery systems that interested the drug companies, of course, but a multitude of other pharmacological applications as well.